M. Frick et al., The effect of oral magnesium, alone or as an adjuvant to sotalol, after cardioversion in patients with persistent atrial fibrillation, EUR HEART J, 21(14), 2000, pp. 1177-1185
Aims To determine whether magnesium given orally decreases the recurrence r
ate of atrial fibrillation after elective direct current cardioversion of p
ersistent atrial fibrillation.
Methods and Results Consecutive outpatients were randomized to treatment wi
th oral magnesium (10.3 mmol) or placebo twice daily in a double-blind fash
ion. Two groups were studied; magnesium study: 170 patients with atrial fib
rillation persistent for >1 month, scheduled for their first direct current
cardioversion. No concomitant antiarrhythmic drugs of class I or III were
allowed. Sotalol and magnesium study: 131 patients with recurrence of persi
stent atrial fibrillation after previous direct current cardioversion, or a
history of paroxysmal atrial fibrillation, treated with sotalol. Patients
were followed until recurrence of atrial fibrillation or for at least 6 mon
ths. Magnesium study: at cardioversion 67 of 85 (79%) in the placebo group
and 64 of 85 (75%) in the magnesium group had converted to sinus rhythm. At
the end of the study, with a follow-up of 6 to 42 months, 15% of patients
in the placebo group and 19% of patients in the magnesium group remained in
sinus rhythm (Log rank test: P=0.37). Sotalol and magnesium study: pharmac
ological conversion to sinus rhythm, after oral treatment, was achieved in
34 of 131 (26%) patients. Sinus rhythm. with or without cardioversion, was
restored in 89% and 85% of the patients in the placebo and magnesium groups
, respectively. At the end of the study, with a follow-up of 6 to 42 months
, 37% of patients in the placebo group and 30% of patients in the magnesium
group remained in sinus rhythm (Log rank test: P=0.64).
Conclusion In patients with persistent atrial fibrillation, oral treatment
with magnesium alone or as an adjuvant to sotalol, does not influence the r
ecurrence rate of atrial fibrillation after elective cardioversion. (Eu Hea
rt J 2000; 21: 1177-1185) (C) 2000 The European Society of Cardiology.